Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target

Bibliography

• Glass CK, Saijo K, Winner B, Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918-34
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27:119-45
   PubMed Web of Science ®Google Scholar
• Dawson TM, Dawson VL, Snyder SH. Molecular mechanisms of nitric oxide actions in the brain. Ann NY Acad Sci 1994;738:76-85
   PubMed Web of Science ®Google Scholar
• Babior BM. NADPH oxidase: an update. Blood 1999;93:1464-76
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Tago H, Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195-200
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schwab C, Parent A, Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003;54:599-604
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Drake J, Pocernich C, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001;7:548-54
   PubMed Web of Science ®Google Scholar
• Park L, Anrather J, Zhou P, NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 2005;25:1769-77
   PubMed Web of Science ®Google Scholar
• Shimohama S, Tanino H, Kawakami N, Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 2000;273:5-9
   PubMed Web of Science ®Google Scholar
• Wu DC, Teismann P, Tieu K, NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:6145-50
   PubMed Web of Science ®Google Scholar
• Wu DC, Re DB, Nagai M, The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA 2006;103:12132-7
   PubMed Web of Science ®Google Scholar
• Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee DY, Chung ES, Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 2005;95:1755-65
   PubMed Web of Science ®Google Scholar
• Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005;25:299-307
   PubMed Web of Science ®Google Scholar
• Qian L, Xu Z, Zhang W, Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 2007;4:23
   PubMed Web of Science ®Google Scholar
• Qin L, Liu Y, Qian X, Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann NY Acad Sci 2005;1053:107-20
   PubMed Web of Science ®Google Scholar
• Qin L, Block ML, Liu Y, Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005;19:550-7
   PubMed Web of Science ®Google Scholar
• Yang S, Yang J, Yang Z, Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther 2006;319:595-603
   PubMedGoogle Scholar
• Stefanska J, Pawliczak R. Apocynin: molecular aptitudes. Mediators Inflamm 2008;2008:106507
   PubMed Web of Science ®Google Scholar
• Stolk J, Rossie W, Dijkman JH. Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema. Am J Respir Crit Care Med 1994;150:1628-31
   PubMed Web of Science ®Google Scholar
• Salmon M, Koto H, Lynch OT, Proliferation of airway epithelium after ozone exposure: effect of apocynin and dexamethasone. Am J Respir Crit Care Med 1998;157:970-7
   PubMed Web of Science ®Google Scholar
• Lo W, Bravo T, Jadhav V, NADPH oxidase inhibition improves neurological outcomes in surgically-induced brain injury. Neurosci Lett 2007;414:228-32
   PubMed Web of Science ®Google Scholar
• Tang XN, Cairns B, Cairns N, Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience 2008;154:556-62
   PubMed Web of Science ®Google Scholar
• Titova E, Ostrowski RP, Sowers LC, Effects of apocynin and ethanol on intracerebral haemorrhage-induced brain injury in rats. Clin Exp Pharmacol Physiol 2007;34:845-50
   PubMed Web of Science ®Google Scholar
• Wang Q, Tompkins KD, Simonyi A, Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res 2006;1090:182-9
   PubMed Web of Science ®Google Scholar
• Zheng JS, Zhan RY, Zheng SS, Inhibition of NADPH oxidase attenuates vasospasm after experimental subarachnoid hemorrhage in rats. Stroke 2005;36:1059-64
   PubMedGoogle Scholar
• Wang Q, Sun AY, Simonyi A, Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J Neurosci Res 2005;82:138-48
   PubMed Web of Science ®Google Scholar
• Li G, Cui G, Tzeng NS, Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 2005;19:489-96
   PubMedGoogle Scholar
• Liu Y, Qin L, Li G, Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 2003;305:212-18
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang T, Qin L, Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004;18:589-91
   PubMed Web of Science ®Google Scholar
• Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev 2007;13:96-106
   PubMedGoogle Scholar
• Thomas DM, Kuhn DM. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005;1050:190-8
   PubMed Web of Science ®Google Scholar
• Jiao XY, Gao E, Yuan Y, INO-4885 [5,10,15,20-tetra[N-(benzyl-4′-carboxylate)-2-pyridinium]-21H,23H-porphine iron(III) chloride], a peroxynitrite decomposition catalyst, protects the heart against reperfusion injury in mice. J Pharmacol Exp Ther 2009;328:777-84
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein JB, Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85:1394-401
   PubMed Web of Science ®Google Scholar
• Astra Zeneca Pharmaceuticals. Use of derivatives of 2, 4-dihydro-[1, 2, 4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO). USPTO20070093483; 2007
   Google Scholar
• Astra Zeneca Pharmaceuticals. Thioxanthine derivatives and their use as inhibitors of MPO. USPTO20090286813; 2009
   Google Scholar
• Genkyo Tex SA. Pyrazolo pyridine derivatives as NADPH oxidase inhibitors. USPTO20100048560; 2010
   Google Scholar
• Genkyo Tex SA. Tetrahydroindole derivatives as NADPH oxidase inhibitors. USPTO20100120749; 2010
   Google Scholar
• McCarty M. Composition for inhibiting NADPH oxidase activity. WO2008063514; 2008
   Google Scholar
• Emory University. Use of Imipramine blue analogs thereof in treating cancers. USPTO20100160296; 2010
   Google Scholar
• Astellas Pharma, Inc. Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity. US20080234237A1; 2008
   Google Scholar
• Astellas Pharma, Inc. Quinolone derivative. WO2009041521; 2009
   Google Scholar
• Emory University. Fulvene and Fulvalene analogs and their use in treating cancers. WO2008137740A1; 2008
   Google Scholar
• Kao Corp. NADH/NADPH Oxidase inhibitor. JP2009007256; 2009
   Google Scholar
• Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting NADPH oxidase expression. WO2008152636A3; 2008
   Google Scholar
• Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625
   PubMed Web of Science ®Google Scholar
• Zhang R, Brennan ML, Shen Z, Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002;277:46116-22
   PubMed Web of Science ®Google Scholar
• Choi DK, Pennathur S, Perier C, Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 2005;25:6594-600
   PubMed Web of Science ®Google Scholar
• Maki RA, Tyurin VA, Lyon RC, Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem 2009;284:3158-69
   PubMed Web of Science ®Google Scholar
• Matthijsen RA, Huugen D, Hoebers NT, Myeloperoxidase is critically involved in the induction of organ damage after renal ischemia reperfusion. Am J Pathol 2007;171:1743-52
   PubMed Web of Science ®Google Scholar
• Reynolds WF, Hiltunen M, Pirskanen M, MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 2000;55:1284-90
   PubMedGoogle Scholar
• Reynolds WF, Rhees J, Maciejewski D, Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999;155:31-41
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Miyazaki Y, Ando K, Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein. Leukemia 2008;22:956-64
   PubMedGoogle Scholar
• El Kebir D, Jozsef L, Pan W, Myeloperoxidase delays neutrophil apoptosis through CD11b/CD18 integrins and prolongs inflammation. Circ Res 2008;103:352-9
   PubMed Web of Science ®Google Scholar
• Hirche TO, Gaut JP, Heinecke JW, Myeloperoxidase plays critical roles in killing Klebsiella pneumoniae and inactivating neutrophil elastase: effects on host defense. J Immunol 2005;174:1557-65
   PubMed Web of Science ®Google Scholar
• Lau D, Mollnau H, Eiserich JP, Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005;102:431-6
   PubMed Web of Science ®Google Scholar
• Green PS, Mendez AJ, Jacob JS, Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004;90:724-33
   PubMed Web of Science ®Google Scholar
• Nagra RM, Becher B, Tourtellotte WW, Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107
   PubMed Web of Science ®Google Scholar
• Gurel A, Armutcu F, Sahin S, Protective role of alpha-tocopherol and caffeic acid phenethyl ester on ischemia-reperfusion injury via nitric oxide and myeloperoxidase in rat kidneys. Clin Chim Acta 2004;339:33-41
   PubMed Web of Science ®Google Scholar
• Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999;133:321-5
   PubMed Web of Science ®Google Scholar
• Cuperus RA, Muijsers AO, Wever R. The effect of D-penicillamine on human myeloperoxidase, a mechanism for the efficacy of the drug in rheumatoid arthritis. Biochim Biophys Acta 1983;749:18-23
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991;41:1485-92
   PubMed Web of Science ®Google Scholar
• Van Zyl A, Lubbe S, Potgieter A, The influence of non-steroidal anti-inflammatory and antithyroid agents on myeloperoxidase-catalysed activities of human leucocytes. S Afr Med J 1979;55:1082-7
   PubMed Web of Science ®Google Scholar
• Matheson NR. The effect of antiarthritic drugs and related compounds on the human neutrophil myeloperoxidase system. Biochem Biophys Res Commun 1982;108:259-65
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 1985;840:204-10
   PubMed Web of Science ®Google Scholar
• Pincemail J, Deby C, Thirion A, Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. Experientia 1988;44:450-3
   PubMedGoogle Scholar
• Capeillere-Blandin C. Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. Biochem J 1998;336(Pt 2):395-404
   PubMedGoogle Scholar
• Astra Zeneca Pharmaceuticals. Pyrrolo [3, 2-D] pyrimidin-4-one derivatives as MPO inhibitors. USPTO20090124640; 2009
   Google Scholar
• Sankyo Corp. New myeloperoxidase inhibitors and method for producing the same. JP2001131133A; 2001
   Google Scholar
• Signum Biosciences, Inc. Acetyl mimic componds for the inhibition of Isoprenyl-S-Cysteinyl methyltransferase. WO2009102997; 2009
   Google Scholar
• Agarwal S, Reddy GV, Reddanna P. Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev Clin Immunol 2009;5:145-65
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s-110s
   PubMed Web of Science ®Google Scholar
• Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179-91
   PubMed Web of Science ®Google Scholar
• Reddy RN, Mutyala R, Aparoy P, Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. Curr Pharm Des 2007;13:3505-17
   PubMedGoogle Scholar
• Kalgutkar AS, Crews BC, Rowlinson SW, Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 2000;97:925-30
   PubMedGoogle Scholar
• Tomimoto H, Akiguchi I, Wakita H, Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol 2000;99:26-30
   PubMedGoogle Scholar
• Temel SG, Kahveci Z. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol 2009;40:369-77
   PubMed Web of Science ®Google Scholar
• Hsiao HY, Mak OT, Yang CS, TNF-alpha/IFN-gamma-induced iNOS expression increased by prostaglandin E2 in rat primary astrocytes via EP2-evoked cAMP/PKA and intracellular calcium signaling. Glia 2007;55:214-23
   PubMedGoogle Scholar
• Raz A, Wyche A, Siegel N, Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 1988;263:3022-8
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L, Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73
   PubMed Web of Science ®Google Scholar
• Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009;30:174-81
   PubMed Web of Science ®Google Scholar
• Yang H, Chen C. Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008;14:1443-51
   PubMed Web of Science ®Google Scholar
• Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002;9:1033-43
   PubMed Web of Science ®Google Scholar
• DeWitt DL. Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 1999;55:625-31
   PubMed Web of Science ®Google Scholar
• Myint AM, Steinbusch HW, Goeghegan L, Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007;14:65-71
   PubMed Web of Science ®Google Scholar
• Gobbo OL, O'Mara SM. Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor celecoxib markedly enhances functional recovery from kainic acid-induced neurodegeneration. Neuroscience 2004;125:317-27
   PubMed Web of Science ®Google Scholar
• Sanchez-Pernaute R, Ferree A, Cooper O, Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004;1:6
   PubMedGoogle Scholar
• Reksidler AB, Lima MM, Zanata SM, The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007;560:163-75
   PubMed Web of Science ®Google Scholar
• Kelsen J, Kjaer K, Chen G, Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response? J Neuroinflammation 2006;3:31
   PubMedGoogle Scholar
• Kumar A, Seghal N, Padi SV, Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacol 2006;551:58-66
   PubMed Web of Science ®Google Scholar
• Bartolini W, Cali BM, Chen B, Useful indole compounds. US20090264653A1; 2009
   Google Scholar
• Microbia, Inc. Modulators of CRTH2, COX-2 and FAAH. WO2006036994A2; 2006
   Google Scholar
• Stephenson DT, Isakson PC, Maziasz TJ, Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX-2) inhibitor(s). US20040034083A1; 2004
   Google Scholar
• Aid S, Langenbach R, Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 2008;5:17
   PubMedGoogle Scholar
• Blais V, Turrin NP, Rivest S. Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem 2005;95:1563-74
   PubMedGoogle Scholar
• Tuo J, Tuaillon N, Shen D, Endotoxin-induced uveitis in cyclooxygenase-2-deficient mice. Invest Ophthalmol Vis Sci 2004;45:2306-13
   PubMedGoogle Scholar
• Gu B, Desjardins P, Butterworth RF. Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide. Metab Brain Dis 2008;23:175-87
   PubMedGoogle Scholar
• Pu H, Hayashi K, Andras IE, Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Brain Res 2007;1184:333-44
   PubMed Web of Science ®Google Scholar
• Werz O, Steinhilber D. Development of 5-lipoxygenase inhibitors–lessons from cellular enzyme regulation. Biochem Pharmacol 2005;70:327-33
   PubMed Web of Science ®Google Scholar
• Uz T, Dimitrijevic N, Tueting P, 5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior. Restor Neurol Neurosci 2002;20:15-20
   PubMedGoogle Scholar
• Firuzi O, Zhuo J, Chinnici CM, 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 2008;22:1169-78
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang WP, Hu H, Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 2006;26:99-106
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wei EQ, Fang SH, Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 2006;79:1645-56
   PubMed Web of Science ®Google Scholar
• Ge QF, Wei EQ, Zhang WP, Activation of 5-lipoxygenase after oxygen-glucose deprivation is partly mediated via NMDA receptor in rat cortical neurons. J Neurochem 2006;97:992-1004
   PubMedGoogle Scholar
• Imbesi M, Zavoreo I, Uz T, 5-Lipoxygenase inhibitor MK-886 increases GluR1 phosphorylation in neuronal cultures in vitro and in the mouse cortex in vivo. Brain Res 2007;1147:148-53
   PubMedGoogle Scholar
• Aparoy P, Kumar Reddy K, Kalangi SK, Pharmacophore modeling and virtual screening for designing potential 5-Lipoxygenase inhibitors. Bioorg Med Chem Lett 2010;20:1013-18
   PubMedGoogle Scholar
• Tu XK, Yang WZ, Shi SS, 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res 2009;31:848-52
   PubMed Web of Science ®Google Scholar
• Jatana M, Giri S, Ansari MA, Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation 2006;3:12
   PubMed Web of Science ®Google Scholar
• West M, Mhatre M, Ceballos A, The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem 2004;91:133-43
   PubMed Web of Science ®Google Scholar
• Klegeris A, McGeer PL. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 2002;23:787-94
   PubMed Web of Science ®Google Scholar
• Cortes-Burgos LA, Zweifel BS, Settle SL, CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. Eur J Pharmacol 2009;617:59-67
   PubMed Web of Science ®Google Scholar
• Galileo Pharmaceuticals I. Novel lipoxygenase inhibitors. WO2006093547A2; 2006
   Google Scholar
• Galileo Pharmaceuticals I. Spiro-heterocyclic chromans, thiochromans and dihydroquinolines. WO2006093548Al; 2006
   Google Scholar
• Chu DTW, James DR, Wang B. Spiro-heterocyclic chromans, thiochromans and ditydroquinolines. US20080207588A1; 2008
   Google Scholar
• Galileo Pharmaceuticals I. Spiro derivatives as lipoxygenase inhibitors. WO2006065686A2; 2006
   Google Scholar
• Chu DTW, Chen J, Zhang W, Spiro deribatives as lipoxygenase inhibitors. US20060128790A1; 2006
   Google Scholar
• Pfizer, Inc. Pyrazole derivatives as 5-LOX inhibitors. WO2009069044Al; 2009
   Google Scholar